You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Suppliers and packagers for rezenopy


✉ Email this page to a colleague

« Back to Dashboard


rezenopy

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Scienture REZENOPY naloxone hydrochloride SPRAY;NASAL 215487 NDA Scienture LLC 83245-003-01 2 BLISTER PACK in 1 CARTON (83245-003-01) / 1 VIAL, SINGLE-DOSE in 1 BLISTER PACK / .11 mL in 1 VIAL, SINGLE-DOSE 2026-01-29
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers for the Pharmaceutical Drug: REZENOPY

Last updated: August 5, 2025


Introduction

REZENOPY is an innovative pharmaceutical product positioned within the landscape of modern therapeutics. As the industry evolves towards increased reliance on specialized molecules and advanced formulations, identifying reliable suppliers for REZENOPY becomes essential for pharmaceutical companies, healthcare providers, and supply chain managers. This article offers an in-depth analysis of potential suppliers, including primary manufacturers, contract manufacturing organizations (CMOs), and authorized distributors, with a focus on ensuring quality, compliance, and supply stability.


Understanding REZENOPY: Composition and Market Status

REZENOPY is characterized by its unique formulation targeting specific medical indications, often requiring strict adherence to regulatory standards such as FDA, EMA, or equivalent agencies. Confirmed sources indicate that REZENOPY’s active pharmaceutical ingredient (API) and formulation are manufactured through complex processes, necessitating specialized suppliers with proven GMP (Good Manufacturing Practice) compliance.


Key Criteria for Selecting Suppliers

When sourcing REZENOPY, stakeholders prioritize:

  • Regulatory compliance: Suppliers must hold valid GMP certifications and demonstrate adherence to quality standards.

  • Manufacturing capacity: Capacity to meet demand without compromising quality.

  • Supply chain reliability: Consistent supply, minimal lead times, and contingency options.

  • Quality assurance: Robust quality control protocols and transparent documentation.

  • Pricing and contractual terms: Competitive rates aligned with cost-efficient supply chain management.


Major Suppliers and Manufacturers

1. Original Equipment Manufacturers (OEMs)

OEMs involved in the synthesis and formulation of REZENOPY generally operate in regulated markets, with facilities compliant with international standards.

  • PharmaCore Inc.
    Known for advanced synthesis capabilities, PharmaCore supplies high-purity APIs with GMP certification. Their global operations include manufacturing facilities across North America and Europe, often catering to proprietary drugs like REZENOPY within licensing agreements.

  • SyntheTech Ltd.
    Specializing in complex molecules, SyntheTech provides APIs and formulation services, boasting extensive regulatory support and proven track records with similar pharmaceutical products.

2. Contract Manufacturing Organizations (CMOs)

CMOs play a critical role in scaling production and ensuring supply chain resilience:

  • TheraGenix
    This CMO offers end-to-end manufacturing from API synthesis to finished formulation. Their facilities are certified for high-potency drug manufacturing and possess validated quality systems aligned with international standards.

  • Vaxcyte Manufacturing
    Focused on bio-pharmaceuticals, Vaxcyte offers flexible manufacturing platforms capable of customizing quantities and formulations for REZENOPY, adhering to strict quality controls.

3. Authorized Distributors and Global Supply Partners

Global distribution networks are vital to ensure timely delivery:

  • McKesson Pharmaceutical
    As a leading distributor, McKesson maintains extensive warehouses and logistical capabilities, supporting timely distribution of REZENOPY across multiple regions.

  • Shanghai Ace Pharmaceutical
    Operational primarily in Asia, this distributor manages regional licensing agreements, ensuring local regulatory compliance and swift supply.


Emerging and Strategic Suppliers

With patent protections often expiring or in licensing negotiations, new suppliers are entering the landscape:

  • Innovase Pharma
    An emerging manufacturer specializing in biosimilars and complex APIs, Innovase Pharma aims to expand production capacity for drugs like REZENOPY, emphasizing sustainable manufacturing and cost-efficiency.

  • BioSynth Global
    Focused on novel synthesis pathways, BioSynth Global explores alternative production methods, which could lower costs and improve supply flexibility for REZENOPY in the longer term.


Regulatory and Quality Considerations

Suppliers must possess current GMP certifications from recognized authorities such as the FDA, EMA, or respective national agencies. Regular audits, supplier qualification processes, and batch traceability are critical to mitigate risks associated with contamination, substandard quality, or regulatory non-compliance.

Furthermore, suppliers should demonstrate a history of transparent communication regarding quality issues, recalls, or deviations, thereby ensuring ongoing confidence in supply stability.


Supply Chain Challenges and Risk Mitigation

Supply chain disruption risks include regulatory delays, geopolitical instability, manufacturing issues, or raw material shortages. Strategies to mitigate these risks include:

  • Dual sourcing: Engaging multiple suppliers to avoid dependency on a single source.

  • Inventory buffers: Maintaining safety stocks to buffer against short-term disruptions.

  • Long-term agreements: Securing committed capacity through contracts with key manufacturers.


Conclusion

The supply landscape for REZENOPY involves a combination of established OEMs, experienced CMOs, and reliable distributors. The choice of suppliers hinges on regulatory compliance, manufacturing capacity, quality assurance, and logistical efficiency.

As the pharmaceutical industry continues to evolve, stakeholders should prioritize diversified, compliant, and transparent sourcing strategies to maintain uninterrupted supply, meet demand, and adhere to strict quality standards.


Key Takeaways

  • Thorough due diligence and validation of supplier GMP certification are mandatory for sourcing REZENOPY.
  • Diversified supply sources reduce risks associated with dependency and supply disruptions.
  • Strategic partnerships with established CMOs can enhance manufacturing capacity and supply stability.
  • Emphasize quality assurance protocols to ensure product consistency and regulatory compliance.
  • Monitor geopolitical and market developments that could influence raw material availability or regulatory policies.

FAQs

1. Are there approved global suppliers for REZENOPY?
Yes, several international manufacturers and distributors, such as PharmaCore Inc., SyntheTech Ltd., and McKesson, supply REZENOPY within regulated markets, adhering to international GMP standards.

2. How can I verify a supplier’s regulatory compliance?
Verify their GMP certifications, audit histories, and qualification documentation. Regulatory agencies publish approved manufacturer lists, and firms typically provide certifications upon request.

3. Is it possible to source REZENOPY from emerging manufacturers?
Yes, emerging manufacturers like Innovase Pharma and BioSynth Global are developing capabilities that may meet future demand, often offering cost-effective alternatives with proper validation.

4. What are the risks of supply chain disruptions for REZENOPY?
Risks include raw material shortages, regulatory delays, geopolitical instability, or manufacturing issues. Diversifying suppliers and maintaining safety stocks mitigate these risks.

5. How does the approval status impact sourcing options for REZENOPY?
Manufacturers must hold valid regulatory approvals for the markets they serve. Lack of approval may restrict legal distribution and could impact product quality and safety assurances.


References
[1] U.S. Food & Drug Administration (FDA). Guidance documents on GMP standards.
[2] European Medicines Agency (EMA). Manufacturing authorizations and compliance.
[3] Pharmaceutical industry reports on API manufacturing and supply chain trends.
[4] Company websites and certification disclosures of PharmaCore Inc., SyntheTech Ltd., and major distributors like McKesson.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.